baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BNP Paribas Discount Zert LONN 27.../ DE000PC73WS2 /

11/8/2024 4:20:38 PM	Chg.+2.940	Bid11/8/2024	Ask11/8/2024	Underlying	Strike price	Expiration date	Option type
514.920EUR	+0.57%	514.920 Bid Size: 436	515.020 Ask Size: 436	LONZA N	- CHF	3/27/2025	Call

GlobeNewswire 8/26 Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences

GlobeNewswire 8/23 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...

GlobeNewswire 8/8 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8/6 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 6/14 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...

GlobeNewswire 6/13 Repligen Announces CEO Transition Plan

GlobeNewswire 5/30 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...

GlobeNewswire 5/15 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...

GlobeNewswire 5/8 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/8 Maravai LifeSciences Reports First Quarter 2024 Financial Results

GlobeNewswire 4/4 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 4/4 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...

GlobeNewswire 2/27 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 2/15 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 1/4 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 12/19/2023 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...

GlobeNewswire 12/9/2023 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...

GlobeNewswire 12/7/2023 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...

GlobeNewswire 12/7/2023 Business Update

GlobeNewswire 11/6/2023 Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 11/1/2023 Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO

GlobeNewswire 10/19/2023 Viralgen welcomes back Andy Holt as CCO

GlobeNewswire 10/16/2023 Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...

GlobeNewswire 10/2/2023 Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

GlobeNewswire 9/20/2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

BNP Paribas Discount Zert LONN 27.../ DE000PC73WS2 /

If you wish to receive reply to your feedback, please provide your email address.